Manufacturer
BAXTER HEALTHCARE CORPORATION
Contents
Sevoflurane
Indication
Induction and maintenance of general anaesthesia
Instruction
Inhalation Induction: Premedicated patient: Up to 5% v/v with oxygen (or mixture of oxygen and nitrous oxide), individualised and titrated to the desired effect according to age and clinical status. Unpremedicated patient: Up to 8% v/v. Maintenance: 0.5-3% v/v with or without nitrous oxide. Doses are administered via calibrated vaporiser. Individualise dose according to patient response.
Drug interaction
Increased metabolism and toxicity w/ drugs that induce CYP2E1 isoenzyme (e.g. isoniazid). Reduced MAC w/ benzodiazepines, opioids. May cause ventricular arrhythmia w/ β-sympathomimetic agents (e.g. isoprenaline), and α- and β-sympathomimetic agents (e.g. adrenaline, noradrenaline). May cause crisis during operation w/ nonselective MAO inhibitors. May lead to marked hypotension and risk of additive negative inotropic effect w/ Ca antagonists (esp dihydropyridines).Potentially Fatal: Rarely, may cause increased serum K levels resulting to cardiac arrhythmia w/ concomitant use of succinylcholine.
Malaysia
